Multikinase Inhibitor Crizotinib Is Active in MET Exon 14-Altered Lung Cancer
- PMID: 31980568
- DOI: 10.1158/2159-8290.CD-RW2020-015
Multikinase Inhibitor Crizotinib Is Active in MET Exon 14-Altered Lung Cancer
Abstract
Crizotinib showed efficacy in non-small cell lung cancer (NSCLC) with alterations in MET exon 14.
©2020 American Association for Cancer Research.
Comment on
-
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13. Nat Med. 2020. PMID: 31932802 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
